Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

GeoVax Labs, Inc. New (GOVX)

Pharmaceutical Preparations

https://www.geovax.com

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

1900 LAKE PARK DRIVE, SUITE 380
SMYRNA, GA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/25/2020

Market Cap

28,999,302

Shares Outstanding

29,660,000

Weighted SO

29,657,287

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

EFTR --.--%

VIRI --.--%

ZURA --.--%

NAVB --.--%

ZVSA --.--%

PHIO --.--%

SONN --.--%

ATNF --.--%

CDIO --.--%

Beta

3.1030

Last Div

0.0000

Range

1.09-9.75

Chg

2.1593

Avg Vol

3686450

Mkt Cap

28999302

Exch

NASDAQ

Country

US

Phone

678 384 7220

DCF Diff

-0.2007

DCF

3.5507

Div Yield

0.0000

P/S

71.6760

EV Multiple

-1.0155

P/FV

-6.0596

Div Yield %

0.0000

P/E

-0.5199

PEG

0.0339

Payout

0.0000

Current Ratio

0.6001

Quick Ratio

0.6001

Cash Ratio

0.2439

DSO

271.2558

DIO

0.0000

Op Cycle

271.2558

DPO

17550.1689

CCC

-17278.9131

Gross Margin

0.7952

Op Margin

-67.3246

Pretax Margin

-66.5253

Net Margin

-66.5253

Eff Tax Rate

-0.0108

ROA

-6.5726

ROE

-8.5258

ROCE

11.7956

NI/EBT

1.0000

EBT/EBIT

0.9881

EBIT/Rev

-67.3246

Debt Ratio

0.0340

D/E

-0.0603

LT Debt/Cap

0.0000

Total Debt/Cap

-0.0641

Int Coverage

-120.8433

CF/Debt

-165.2576

Equity Multi

-1.7734

Rec Turnover

1.3456

Pay Turnover

0.0208

Inv Turnover

0.0000

FA Turnover

2.3724

Asset Turnover

0.0988

OCF/Share

-9.0549

FCF/Share

-9.0648

Cash/Share

0.6149

OCF/Sales

-56.8439

FCF/OCF

1.0011

CF Coverage

-165.2576

ST Coverage

-165.2576

CapEx Coverage

-914.7767

Div&CapEx Cov

-914.7767

P/BV

-6.0596

P/B

-6.0596

P/S

71.6760

P/E

-0.5199

P/FCF

-1.2595

P/OCF

-0.6084

P/CF

-0.6084

PEG

0.0339

P/S

71.6760

EV Multiple

-1.0155

P/FV

-6.0596

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Aug 29, 00:59 GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market GlobeNewswire Inc. Dec 27, 09:00 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 GlobeNewswire Inc. Nov 30, 16:30 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

Revenue Product Segmentation